Dental CE Course: SECOND BMP SYMPOSIUM 2011

After numerous animal and human research studies that first began in 1965, the Food and Drug Administration (FDA) cleared recombinant human Bone Morphogenetic Protein-2/ACS (rhBMP-2/ACS) for two dental and oral and maxillofacial surgery indications (socket grafting and sinus augmentation) in March of 2007. In just three short years, it has met and even exceeded its clinical promise of bone regeneration without using the patient’s own bone. Extended applications into horizontal and vertical ridge augmentations, ridge splitting, implant salvage, alveolar clefts, orthognathic surgery, continuity defects, and salvaging inadequate grafts have shown that rhBMP-2/ACS can replace autogenous grafting in many other applications thereby providing a reduced complication potential and morbidity for such patients. This course is designed to present the specifics of indications, techniques to be used, doses, co-materials, costs, and outcomes for these extended applications, by the researchers and clinicians with the most thorough scientific and clinical experience using rhBMP-2/ACS. This course should provide the necessary information and examples so that attendees can assess each of their own patients as to the potential use and limitations in using rhBMP-2/ACS.